Cardiol Therapeutics Inc.
TSX:CRDL.TODrug Manufacturers - Specialty & Generic
Healthcare
$1.36 +0.67%
+$0.00 today
- Market cap
- $164.10M
- Beta
- 0.48
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.33
52W Low $1.23High $2.33
Volume 0.08M
Average 0.12M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$23.85M
FY 2025 · Annual
Investing Cash Flow
-$24,484.00
FY 2025 · Annual
Financing Cash Flow
$15.54M
FY 2025 · Annual
-17.5% YoYCash Flow Statement
CAD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (31.64M) | (30.93M) | (28.13M) | (36.68M) | (33.82M) |
| Depreciation & Amortization | 220.42K | 219.91K | 248.36K | 373.11K | 101.98K |
| Deferred Income Tax | (4.92M) | 0 | (1.59M) | 0 | 0 |
| Stock-Based Compensation | 8.5M | 5.01M | 4.17M | 14.28M | 10.7M |
| Change in Working Capital | 76.52K | 5.75M | 746.8K | (931.57K) | (733.34K) |
| Accounts Receivables | (59.95K) | (144.18K) | 67.18K | (81.75K) | 135.43K |
| Inventory | 17.97K | (4.47M) | 0 | 0 | 0 |
| Accounts Payables | 2.39M | 4.47M | (1.29M) | (1.06M) | 263.69K |
| Other Working Capital | (2.27M) | 5.89M | 679.62K | 214.93K | (1.13M) |
| Other Non-Cash Items | 4.21M | (7.27M) | (627.28K) | (2.1M) | (105.34K) |
| Operating Cash Flow | (23.55M) | (27.22M) | (25.18K) | (25.06M) | (23.85M) |
| Capital Expenditures | (12.92K) | (74.71K) | (64) | (21.29K) | (24.48K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (64.25K) | 0 | 0 |
| Investing Cash Flow | (12.92K) | (74.71K) | (64.31K) | (21.29K) | (24.48K) |
| Debt Repayment | (51.92K) | (53.93K) | (55.38K) | (41.53K) | (55.38K) |
| Common Stock Issued | 84.08M | 0 | 0 | 21.36M | 16.07M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.35M | 0 | (55.38K) | (2.47M) | (477.03K) |
| Financing Cash Flow | 93.44M | (53.93K) | (55.38K) | 18.84M | 15.54M |
| Effect of Forex Changes | (11.13K) | 2.92M | 762.04K | 1.89M | (824.04K) |
| Net Change in Cash | 69.87M | (24.43M) | (24.54M) | (4.35M) | (9.16M) |
| Free Cash Flow | (23.56M) | (27.3M) | (25.24K) | (25.08M) | (23.88M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$33.8M
+ D&A$102.0K
+ Stock-Based Comp$10.7M
+ Deferred Tax$0
- Working Capital-$733.3K
- Other Non-Cash-$105.3K
= Operating Cash Flow-$23.9M
- Capex-$24.5K
= Free Cash Flow-$23.9M
Analysis
FY2025 free cash flow is -$23.9M. FCF conversion is 70.6% of net income. Operating cash flow was -$23.9M, with capex of -$24.5K. The largest bridge item is Stock-Based Comp at $10.7M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
No filings found.
Does CRDL.TO generate free cash flow?
Cardiol Therapeutics Inc. (CRDL.TO) generated -$23.88M of free cash flow in fiscal 2025.
How much operating cash flow does CRDL.TO produce?
Operating cash flow was -$23.85M, before capital expenditures of $24,484.00.
Continue the stock analysis
Jump to another research area for this company.